glp 1 agonist heart disease GLP-1 receptor agonist-based therapies and cardiovascular risk: a review of mechanisms Results of cardiovascular outcomes trials

GIP receptor agonism attenuates GLP-1 receptor agonistinduced nausea and emesis in preclinical models

Most patients regain significant weight within 1 year of stopping without behavioral support (STEP 1 extension data)

One advantage liraglutide holds over the more potent GLP-1 options is the ability to fine-tune dosing on a daily basis

GLP-1 RAs, originally developed to strengthen insulin secretion and manage blood glucose levels, have shown impressive benefits on the far side of glycemic control

References Cava, E., Yeat, N

it illustrates a medications use and efficacy in peoples daily lives.] Hursting: We need more people asking questions in animal models [lab animals used to study aspects of human disease] so we get a bit more clarity around what cancers are most responsive